Can SPhotonix’s optical memory technology protect data better than today’s storage?
Updated
January 8, 2026 6:32 PM
SPhotonix's 5D Memory Crystals™. PHOTO: SPHOTONIX
SPhotonix, a young deep-tech startup, is working on something unexpected for the data storage world: tiny, glass-like crystals that can hold enormous amounts of information for extremely long periods of time. The company works where light and data meet, using photonics—the science of shaping and guiding light—to build optical components and explore a new form of memory called “5D optical storage”.
It’s based on research that began more than twenty years ago, when Professor Peter Kazansky showed that a small crystal could preserve data—from the human genome to the entire Wikipedia—essentially forever.
Their new US$4.5 million pre-seed round, led by Creator Fund and XTX Ventures, is meant to turn that science into real products. And the timing aligns with a growing problem: the world is generating far more digital data than current storage systems can handle. Most of it isn’t needed every day, but it can’t be thrown away either. This long-term, rarely accessed cold data is piling up faster than existing storage infrastructure can manage and maintaining giant warehouses of servers just to keep it all alive is becoming expensive and environmentally unsustainable.
This is the problem SPhotonix is stepping in to solve. They want to store huge amounts of information in a stable format that doesn’t degrade, doesn’t need electricity to preserve data and doesn’t require constant swapping of hardware. Instead of racks of spinning drives, the idea is a durable optical crystal storage system that could last for generations.
The company’s underlying technology—called FemtoEtch™—uses ultrafast lasers to engrave microscopic patterns inside fused silica. These precisely etched structures can function as high-performance optical components for fields like aerospace, microscopy and semiconductor manufacturing. But the same ultra-controlled process can also encode information in five dimensions within the crystal, transforming the material into a compact, long-lasting archive capable of holding massive amounts of information in a very small footprint.
The new funding allows SPhotonix to expand its engineering team, grow its R&D facility in Switzerland and prepare the technology for real-world deployment. Investors say the opportunity is significant: global data generation has more than doubled in recent years and traditional storage systems—drives, disks, tapes—weren’t designed for the scale or longevity modern data demands.
While the company has been gaining attention in research circles (and even made an appearance in the latest Mission Impossible film), its next step is all about practical adoption. If the technology reaches commercial viability, it could offer an alternative to the energy-hungry, short-lived storage hardware that underpins much of today’s digital infrastructure.
As digital information continues to multiply, preserving it safely and sustainably is becoming one of the biggest challenges in modern computing. SPhotonix’s work points toward a future where long-lasting, low-maintenance optical data storage becomes a practical alternative to today’s fragile systems. It offers a more resilient way to preserve knowledge for the decades ahead.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.